In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Police, campus unrest and the power of student protests
The ‘stain’ of foreign interference on Canadian elections
‘What I eat in a day’ videos and the new diet culture
How the politics of decriminalization played out in B.C.
Why running is more popular than ever
Sudan and the neglected wars
The biggest EV investment in Canada yet
City Space: Vancouver’s Chinatown fights gentrification
The call to disband the Thunder Bay police
How Hong Kong is cracking down on dissent
As conflict rages in Gaza, a ‘silent war’ in the West Bank
The capital gains tax, explained
ArriveCan and the government’s outsourcing problem
The stakes of India’s election as Modi seeks third term
What the 2024 federal budget means for you
How a new kind of drug could change the future of Alzheimer’s
City Space: How Halifax’s unhoused crisis got so bad
What we’ve learned from the foreign interference inquiry
Former health minister Jane Philpott’s plan to save health care
Why major economies are trying to woo Vietnam
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire